-
Article
Pharmacokinetic investigation of a nicotine sublingual tablet
Objective: To evaluate the pharmacokinetics of a new 2-mg nicotine sublingual tablet under varying conditions of use. Methods: The pharmacokinetics of the 2-mg nicotine sublingual tablet were in...
-
Article
Site of nicotine absorption from a vapour inhaler – comparison with cigarette smoking
Objective: The aim of the study was to assess the site of nicotine absorption during and after use of a nicotine-vapour inhaler compared with that after cigarette smoking.
-
Article
Temperature dependency of the release and bioavailability of nicotine from a nicotine vapour inhaler; in vitro/ in vivo correlation
Objective: To investigate the temperature dependency of the dose released and the plasma levels of nicotine from a vapour inhaler.
-
Article
Transdermally administered nicotine accumulates in gastric juice
-
Article
Effect of nicotine vapour inhalation on the relief of tobacco withdrawal symptoms
Fifteen subjects participated in a randomised, placebo-controlled cross-over study to assess the effect of a nicotine vapour inhaler on craving and other withdrawal symptoms during a two-day smoking-free perio...
-
Article
Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant
The relative bioavailability of nicotine from a nasal spray was assessed in 15 smokers suffering a common cold and rhinitis according to generally accepted criteria. The patients were given a single dose of 2 ...
-
Article
Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms
Nicotine gum and transdermal nicotine have been shown to relieve withdrawal and double success rates over placebo in trials of smoking cessation. This study tested whether combining the two methods would relie...
-
Article
Additive bronchodilator effects of terbutaline and enprofylline in asthma
Enprofylline is a novel xanthine derivative with negligible adenosine antagonizing ability. It is eliminated almost exclusively by renal clearance with a half-life of about 2 h. Three i.v. infusions of enprofy...
-
Article
Pharmacokinetics of enprofylline in healthy elderly subjects
The pharmacokinetics of enprofylline, a new potent antiasthmatic, has been studied in 20 healthy, elderly subjects, aged 65 to 81 years, and in 7 young adult controls, aged 23 to 37 years. The dose of 1 mg/kg ...
-
Article
Effects of probenecid on enprofylline kinetics in man
Enprofylline 1 mg/kg, a new potent antiasthmatic xanthine derivative, which is mainly eliminated by renal excretion, was given intravenously to 6 normal subjects with and without oral pretreatment with 1 g pro...
-
Article
Absorption of enprofylline from the gastrointestinal tract in healthy subjects
Enprofylline, a new potent bronchodilator xanthine drug, was given orally as an aqueous solution to 6 healthy subjects in single doses of 2, 4 and 6 mg/kg. The two lower doses produced plasma concentrations in...
-
Article
Pharmacokinetics of enprofylline in patients with impaired renal function after a single intravenous dose
Enprofylline, a new bronchodilating drug, was given i.v. at 1.0 mg/kg to 7 healthy subjects and to 14 patients with differing degrees of chronic renal insufficiency. Plasma and urine concentrations of unchange...
-
Article
Effects of enprofylline, a xanthine lacking adenosine receptor antagonism, in patients with chronic obstructive lung disease
Enprofylline, a xanthine-derivative shown experimentally to lack universal adenosine receptor antagonism, has been examined in patients with partly reversible, chronic, obstructive lung disease. Significant br...
